Literature DB >> 2153139

Intracellular turnover, novel secretion, and mitogenically active intracellular forms of v-sis gene product in simian sarcoma virus-transformed cells. Implications for intracellular loop autocrine transformation.

V B Lokeshwar1, S S Huang, J S Huang.   

Abstract

In simian sarcoma virus (SSV)-transformed cells (SSV-NRK, SSV-NIH 3T3, and SSV-NP1 cells), the v-sis gene product was synthesized as a 36-kDa glycopolypeptide with one endoglycosidase (Endo) H-sensitive oligosaccharide chain and formed a dimer (p72) with a half-time of less than 5 min. p72 was proteolytically processed to generate sequentially p68 and p58 in the endoplasmic reticulum/Golgi complex, p44 in the post-Golgi complex compartments, and p27 in an endosomal/lysosomal compartment. A portion (20-30%) of p72 and p68 later became Endo H-resistant but Endo F-sensitive. During processing, the v-sis gene products exhibited rapid turnover, possibly in the endoplasmic reticulum and/or Golgi complex. The rate of turnover correlated with the tumorigenicity previously reported in these SSV-transformed cells. All three SSV-transformed cells secreted v-sis gene product (p44). p44 was secreted but remained tightly associated with the cell surface. This novel secretion provided an efficient system for the interaction of p44 with the cell surface platelet-derived growth factor receptor which resulted in the intracellular formation of p27. A fraction of secreted p44 was converted extracellularly to a 27-kDa product (extracellular p27) after a longer time in culture. The identical N-terminal amino acid sequence of p44 and extracellular p27 (H2N-SLGSLSVAEPAMIA) indicated a preferential site (Lys110-Arg111) for the proteolytic processing. The intracellular turnover of the v-sis gene product and its correlation with tumorigenicity as well as the demonstration of mitogenically active intracellular forms of v-sis gene product support the hypothesis of intracellular loop autocrine transformation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2153139

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

Review 1.  Platelet-derived growth factor: mechanism of action and possible in vivo function.

Authors:  C H Heldin; B Westermark
Journal:  Cell Regul       Date:  1990-07

2.  CRSBP-1/LYVE-1 ligands disrupt lymphatic intercellular adhesion by inducing tyrosine phosphorylation and internalization of VE-cadherin.

Authors:  Wei-Hsien Hou; I-Hua Liu; Cheng C Tsai; Frank E Johnson; Shuan Shian Huang; Jung San Huang
Journal:  J Cell Sci       Date:  2011-04-15       Impact factor: 5.285

Review 3.  The road less travelled: c-kit and stem cell factor.

Authors:  W Hamel; M Westphal
Journal:  J Neurooncol       Date:  1997-12       Impact factor: 4.130

4.  CRSBP-1/LYVE-l-null mice exhibit identifiable morphological and functional alterations of lymphatic capillary vessels.

Authors:  S S Huang; I-Hua Liu; Tracy Smith; Maulik R Shah; Frank E Johnson; Jung S Huang
Journal:  FEBS Lett       Date:  2006-10-20       Impact factor: 4.124

5.  A Novel Splice Variant of HYAL-4 Drives Malignant Transformation and Predicts Outcome in Patients with Bladder Cancer.

Authors:  Vinata B Lokeshwar; Daley S Morera; Sarrah L Hasanali; Travis J Yates; Marie C Hupe; Judith Knapp; Soum D Lokeshwar; Jiaojiao Wang; Martin J P Hennig; Rohitha Baskar; Diogo O Escudero; Ronny R Racine; Neetika Dhir; Andre R Jordan; Kelly Hoye; Ijeoma Azih; Murugesan Manoharan; Zachary Klaassen; Sravan Kavuri; Luis E Lopez; Santu Ghosh; Bal L Lokeshwar
Journal:  Clin Cancer Res       Date:  2020-02-24       Impact factor: 12.531

6.  Reversion of autocrine transformation by a dominant negative platelet-derived growth factor mutant.

Authors:  F S Vassbotn; M Andersson; B Westermark; C H Heldin; A Ostman
Journal:  Mol Cell Biol       Date:  1993-07       Impact factor: 4.272

7.  Identification of a cell retention signal in the B-chain of platelet-derived growth factor and in the long splice version of the A-chain.

Authors:  A Ostman; M Andersson; C Betsholtz; B Westermark; C H Heldin
Journal:  Cell Regul       Date:  1991-07

8.  Dominant-negative mutants of platelet-derived growth factor revert the transformed phenotype of human astrocytoma cells.

Authors:  S M Shamah; C D Stiles; A Guha
Journal:  Mol Cell Biol       Date:  1993-12       Impact factor: 4.272

9.  Positive immunostaining for platelet derived growth factor (PDGF) is an adverse prognostic factor in patients with advanced breast cancer.

Authors:  L Seymour; W R Bezwoda
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

10.  The v-sis oncoprotein loses transforming activity when targeted to the early Golgi complex.

Authors:  K C Hart; Y F Xu; A N Meyer; B A Lee; D J Donoghue
Journal:  J Cell Biol       Date:  1994-12       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.